Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
PI3K inhibitor
DRUG CLASS:
PI3K inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
alpelisib (71)
RTB101 (43)
PF-05212384 (31)
RG7440 (24)
GDC-0941 (22)
chidamide (20)
AN2025 (20)
GSK2126458 (17)
MEN1611 (13)
CUDC-907 (8)
rigosertib (7)
LY294002 (7)
PF-04691502 (6)
RP6530 (6)
LY3023414 (5)
GDC-0980 (4)
A66 (3)
enzastaurin (3)
PI-103 (2)
AEZS 136 (1)
AEZS-129 (1)
AZD8835 (1)
BAY 1082439 (1)
DFN-529 (1)
KU-0060648 (1)
SRX3262 (1)
GDC-0084 (1)
SAR245408 (1)
CBL0102 (1)
alpelisib (71)
RTB101 (43)
PF-05212384 (31)
RG7440 (24)
GDC-0941 (22)
chidamide (20)
AN2025 (20)
GSK2126458 (17)
MEN1611 (13)
CUDC-907 (8)
rigosertib (7)
LY294002 (7)
PF-04691502 (6)
RP6530 (6)
LY3023414 (5)
GDC-0980 (4)
A66 (3)
enzastaurin (3)
PI-103 (2)
AEZS 136 (1)
AEZS-129 (1)
AZD8835 (1)
BAY 1082439 (1)
DFN-529 (1)
KU-0060648 (1)
SRX3262 (1)
GDC-0084 (1)
SAR245408 (1)
CBL0102 (1)
›
Associations
(331)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
PIK3CA mutation
Colorectal Cancer
PIK3CA mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation
Colorectal Cancer
PIK3CA mutation + KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type
Colorectal Cancer
PIK3CA wild-type + KRAS wild-type
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
Oncogene - 3 weeks (New C3)
alpelisib
Sensitive
:
A1
Oncogene - 3wk
alpelisib
Sensitive: A1 - Approval
Oncogene - 3 weeks
alpelisib
Sensitive
:
A1
Oncogene - 3 weeks - (New C3)
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor + alpelisib
Sensitive: A2 - Guideline
CDK6 inhibitor + alpelisib
Sensitive
:
A2
CDK6 inhibitor + alpelisib
Sensitive: A2 - Guideline
CDK6 inhibitor + alpelisib
Sensitive
:
A2
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor + alpelisib
Sensitive: A2 - Guideline
CDK4 inhibitor + alpelisib
Sensitive
:
A2
CDK4 inhibitor + alpelisib
Sensitive: A2 - Guideline
CDK4 inhibitor + alpelisib
Sensitive
:
A2
PIK3CA exon 20 mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA exon 20 mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A2 - Guideline
alpelisib
Sensitive
:
A2
alpelisib
Sensitive: A2 - Guideline
alpelisib
Sensitive
:
A2
PIK3CA exon 7 mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA exon 7 mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A2 - Guideline
alpelisib
Sensitive
:
A2
alpelisib
Sensitive: A2 - Guideline
alpelisib
Sensitive
:
A2
PIK3CA exon 9 mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA exon 9 mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A2 - Guideline
alpelisib
Sensitive
:
A2
alpelisib
Sensitive: A2 - Guideline
alpelisib
Sensitive
:
A2
PIK3CA mutation + HR positive + HER-2 negative
Male Breast Cancer
PIK3CA mutation + HR positive + HER-2 negative
Male Breast Cancer
alpelisib
Sensitive: A2 - Guideline
alpelisib
Sensitive
:
A2
alpelisib
Sensitive: A2 - Guideline
alpelisib
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
RP6530
Sensitive: B - Late Trials
RP6530
Sensitive
:
B
RP6530
Sensitive: B - Late Trials
RP6530
Sensitive
:
B
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
RP6530
Sensitive: B - Late Trials
RP6530
Sensitive
:
B
RP6530
Sensitive: B - Late Trials
RP6530
Sensitive
:
B
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
AN2025
Sensitive: B - Late Trials
AN2025
Sensitive
:
B
AN2025
Sensitive: B - Late Trials
AN2025
Sensitive
:
B
PIK3CA mutation
HER2 Negative Breast Cancer
PIK3CA mutation
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
enzastaurin
Sensitive: B - Late Trials
enzastaurin
Sensitive
:
B
enzastaurin
Sensitive: B - Late Trials
enzastaurin
Sensitive
:
B
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
AN2025
Sensitive: B - Late Trials
AN2025
Sensitive
:
B
AN2025
Sensitive: B - Late Trials
AN2025
Sensitive
:
B
PIK3CA mutation
Breast Cancer
PIK3CA mutation
Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
PI3K inhibitor
Sensitive: B - Late Trials
PI3K inhibitor
Sensitive
:
B
PI3K inhibitor
Sensitive: B - Late Trials
PI3K inhibitor
Sensitive
:
B
AKT1 mutation
Triple Negative Breast Cancer
AKT1 mutation
Triple Negative Breast Cancer
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
PTEN mutation
Triple Negative Breast Cancer
PTEN mutation
Triple Negative Breast Cancer
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
PIK3CA mutation
Triple Negative Breast Cancer
PIK3CA mutation
Triple Negative Breast Cancer
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
GDC-0084
Sensitive: B - Late Trials
GDC-0084
Sensitive
:
B
GDC-0084
Sensitive: B - Late Trials
GDC-0084
Sensitive
:
B
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
chidamide
Sensitive: B - Late Trials
chidamide
Sensitive
:
B
chidamide
Sensitive: B - Late Trials
chidamide
Sensitive
:
B
PIK3CA E542K + HR positive
HER2 Negative Breast Cancer
PIK3CA E542K + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PIK3CA H1047X
HER2 Negative Breast Cancer
PIK3CA H1047X
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PIK3CA E545X
HER2 Negative Breast Cancer
PIK3CA E545X
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PTEN deletion
Prostate Cancer
PTEN deletion
Prostate Cancer
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
PTEN negative
Prostate Cancer
PTEN negative
Prostate Cancer
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
RG7440
Sensitive: B - Late Trials
RG7440
Sensitive
:
B
PIK3CA N345K + PIK3CA N1044K
Breast Cancer
PIK3CA N345K + PIK3CA N1044K
Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PIK3CA G106_108del
Breast Cancer
PIK3CA G106_108del
Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PIK3CA R38C
Breast Cancer
PIK3CA R38C
Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PIK3CA Q75E
Breast Cancer
PIK3CA Q75E
Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
PIK3CA N345K
Breast Cancer
PIK3CA N345K
Breast Cancer
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
alpelisib
Sensitive: B - Late Trials
alpelisib
Sensitive
:
B
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
PF-05212384
Sensitive: B - Late Trials
PF-05212384
Sensitive
:
B
PF-05212384
Sensitive: B - Late Trials
PF-05212384
Sensitive
:
B
PIK3CA mutation + HR positive
Hormone Receptor Positive Breast Cancer
PIK3CA mutation + HR positive
Hormone Receptor Positive Breast Cancer
alpelisib
Sensitive: C1 - Off-label
alpelisib
Sensitive
:
C1
alpelisib
Sensitive: C1 - Off-label
alpelisib
Sensitive
:
C1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login